

DURIE TANGRI LLP
DARALYN J. DURIE (SBN 169825)
ddurie@durietangri.com
CLEMENT S. ROBERTS (SBN 209203)
croberts@durietangri.com
RAGHAV R. KRISHNAPRIYAN (SBN 273411)
rkrishnapriyan@durietangri.com
217 Leidesdorff Street
San Francisco, CA 94111
Telephone: 415-362-6666
Facsimile: 415-236-6300

YOUNG BASILE HANLON & MACFARLANE, P.C.
JEFFREY D. WILSON (*PRO HAC VICE*)
wilson@youngbasile.com
ANDREW R. BASILE, JR. (SBN 208396)
abasile@youngbasile.com
3001 W. Big Beaver Road, Suite 624
Troy, Michigan 48084
Telephone: (248) 649-3333
Facsimile: (248) 649-3338

Attorneys for Plaintiff
PLEXXIKON INC.

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA

PLEXXIKON INC.,	:	Case No. 4:17-cv-04405-HSG (EDL)
	:	
Plaintiff,	:	
	:	
v.	:	
	:	
NOVARTIS PHARMACEUTICALS	:	FIRST AMENDED COMPLAINT FOR
CORPORATION,	:	PATENT INFRINGEMENT
	:	
Defendant.	:	DEMAND FOR JURY TRIAL
	:	

1 Plaintiff Plexxikon Inc. (“Plexxikon”), for its Complaint against Defendant Novartis
2 Pharmaceuticals Corporation (“Novartis”), alleges as follows:

3 **NATURE OF THE ACTION**

4 1. This is an action arising under the patent laws of the United States, codified at 35 U.S.C.
5 §§ 1, *et seq.* for infringement of U.S. Patent No. 9,469,640 (“the ’640 patent”) through Novartis’s
6 importation, offer for sale, and sale of the drug dabrafenib. Novartis markets dabrafenib under the
7 trademark Tafinlar®.

8 **PARTIES**

9 2. Plexxikon is a corporation organized and existing under the laws of the State of California,
10 with its principal place of business at 91 Bolivar Drive, Berkeley, California 94710.

11 3. Novartis Pharmaceuticals Corporation is a corporation organized and existing under the
12 laws of the State of Delaware and has a principal place of business at One Health Plaza, East Hanover,
13 New Jersey 07936. Novartis Pharmaceuticals Corporation is a wholly owned subsidiary of Novartis AG,
14 a corporation organized and existing under the laws of Switzerland with its principal place of business at
15 Lichtstrasse 35, CH-4056 Basel, Switzerland.

16 **JURISDICTION AND VENUE**

17 4. This civil action arises under the patent laws of the United States, 35 U.S.C. § 1, *et seq.*
18 This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1338(a).

19 5. This Court has personal jurisdiction over Novartis pursuant to the laws of the State of
20 California, including California’s long-arm statute (California Code of Civil Procedure § 410.10) because
21 Novartis regularly and continuously transacts business in this jurisdiction, including marketing and selling
22 Tafinlar® throughout the State of California. Novartis derives substantial revenue from its sales in the
23 State of California. Novartis maintains and operates facilities at 150 Industrial Road, San Carlos, CA
24 94070; 5300 Chiron Way, Emeryville, CA 94608; and 10675 John Jay Hopkins Drive, San Diego, CA
25 92121.

26 6. Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391 and 1400 because Novartis
27 has a regular and established place of business within the district and has committed acts of infringement
28 within the district. Novartis maintains and operates at least two facilities within this district, in San Carlos

1 and Emeryville. Novartis's acts of infringement within this district include, but are not limited to, selling
2 and offering to sell the infringing product within the district to its distributor, San Francisco-based
3 McKesson Corporation ("McKesson"). McKesson lists Tafinlar® in its catalog of available products
4 through its distribution division, McKesson Specialty Health, which also has multiple locations within the
5 district. Novartis also employs oncology sales representatives within the district whose customers include
6 office-based physicians, consultant pharmacists, medical directors, and key medical and nursing
7 personnel. The infringing product is also used by healthcare providers and patients within this district.

8 **BACKGROUND**

9 7. Plexxikon is a leader in the discovery and development of novel, small molecule
10 pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop
11 targeted medicines to treat cancer.

12 8. At least as early as 2005, Plexxikon's scientists discovered and started making compounds
13 that reduce the growth of cancer cells that have a mutated form of the BRAF gene. The BRAF gene
14 encodes information used by cells to produce enzymes (called "BRAF kinases") that increase cellular
15 metabolism and growth. The mutated BRAF gene substantially increases BRAF kinase activity, driving
16 the proliferation of cancer cells.


17 9. The compounds Plexxikon discovered target and bind with the BRAF kinase produced by
18 the mutated BRAF gene in a manner that inhibits its activity, and thereby disrupts the cancer cells' ability
19 to metabolize energy. For this reason, the compounds Plexxikon discovered are referred to as "selective
20 BRAF kinase inhibitors."

21 10. Although BRAF kinase inhibitors existed prior to Plexxikon's discoveries, those BRAF
22 kinase inhibitors were not selective and therefore inhibited many different RAF kinases. As a result, those
23 BRAF kinase inhibitors caused severe side effects that prevented them from being used in doses that were
24 high enough to effectively fight the cancer cells.

25 11. In contrast, the selective BRAF kinase inhibitors developed by Plexxikon have a core
26 molecular structure – in particular, a sulfonamide with its nitrogen attached to a halogenated phenyl – that
27 allows them to bind *selectively* to the kinase created by the BRAF^{V600E} (or V600E BRAF) mutation. The
28 BRAF^{V600E} mutation is frequently found in metastatic melanoma and found to a lesser degree in other

forms of non-resectable or metastatic cancers. This BRAF^{V600E} selectivity of Plexxikon's kinase inhibitors allows them to be given in much higher doses, resulting in a far more pharmacologically effective treatment than non-selective BRAF kinase inhibitors.

12. Plexxikon's invention of kinase inhibitors that bind only to the kinase produced by cells with the V600E mutation in the BRAF gene was a true scientific breakthrough that gave hope to patients facing a disease (metastatic melanoma) for which hope had previously been in desperately short supply. For example, USA Today quoted Dr. Lynn Schuchter (the Chief of the Division of Hematology Oncology and the C. Willard Robinson Professor of Hematology-Oncology at the University of Pennsylvania) as saying that Plexxikon's discovery "is the most important breakthrough in melanoma, ever." Liz Szabo, 'Breakthrough' Melanoma Drug Shrinks Tumors, USA TODAY (Aug. 26, 2010, 1:08 AM), http://usatoday30.usatoday.com/news/health/2010-08-26-1Amelanoma26_ST_N.htm. The following before-and-after picture illustrates the dramatic tumor-shrinking in a patient with metastatic melanoma who was treated with vemurafenib, a selective BRAF kinase inhibitor developed by Plexxikon and having the same core molecular structure described above (published by the Economist (Marathon Man Genomics Has Not Yet Delivered the Drugs, but it Will, THE ECONOMIST (Jun. 17, 2010), <http://www.economist.com/node/16349422#print>) as part of its coverage of the breakthrough):



13. The results of treatment with Plexxikon's selective BRAF kinase inhibitors were not merely visually compelling. The New England Journal of Medicine published a study showing that vemurafenib "induced complete or partial tumor regression in 81% of patients who had melanoma with the V600E BRAF mutation" and noted that the "efficacy data [is] particularly encouraging in light of the

high disease burden in most of [the study's] patients.” (Keith T. Flaherty et al., *Inhibition of Mutated, Activated BRAF in Metastatic Melanoma*, 363 NEW ENG. J. MED. 809, 816 (2010)). Similarly, Plexxikon’s vemurafenib was described as a “First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma” by the Journal of the Advanced Practitioner in Oncology. (Lindsay Shelledy et al., *Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma*, J. ADV. PRACT. ONCOL., Jul.-Aug. 2015, at 361-65).

14. Plexxikon licensed vemurafenib to its development partner and began clinical trials in 2006. On August 17, 2011, the Federal Drug Administration (“FDA”) granted approval for the drug for the treatment of patients with unresectable or metastatic melanoma with BRAF^{V600E} mutation as detected by an FDA-approved test. Vemurafenib was the first targeted therapy approved for melanoma.

15. Shortly after vemurafenib won FDA approval, Plexxikon’s development partner began selling it under the trademark Zelboraf[®]. Zelboraf[®] was a medical and commercial success, offering life extending treatment to terminally ill cancer patients with metastatic melanoma and achieving worldwide sales of over \$1,500,000,000 to date. Today Zelboraf[®] is approved in 99 countries and has extended the lives of many thousands of terminally ill cancer patients.

16. To protect its pioneering discovery, Plexxikon filed patent applications as early as June 22, 2005, disclosing novel compounds having the core molecular structure that Plexxikon had invented. Several of those applications matured into patents which cover selective BRAF kinase inhibitors, including some directed to the molecular structure of vemurafenib and one (filed on July 17, 2007) that matured into the ’640 patent at issue in this case.

17. A second application, U.S. patent application serial number 15/260,042, filed by Plexxikon and claiming priority to July 17, 2007, also covers selective BRAF kinase inhibitors including dabrafenib. This application was published as US 2017/0056382 A1 on March 2, 2017, was allowed on July 17, 2017, and currently awaits issuance.

18. The ’640 patent covers a class of selective BRAF kinase inhibitors which selectively bind to the BRAF kinase that results from the V600E mutation. One of the molecules within this class (dabrafenib) was brought to market by Novartis’s predecessor in interest, GlaxoSmithKline plc (“GSK”).


In 2013, GSK received FDA approval to sell dabrafenib for treatment of melanoma and began selling it under the trademark Tafinlar®. Tafinlar® directly competes with Plexxikon's Zelboraf®.

19. GSK transferred a portfolio of oncology drugs, including Tafinlar®, to Novartis in 2015 in exchange for approximately \$16 billion. In June of 2017, Novartis received FDA approval to sell dabrafenib under the trademark Tafinlar® for treatment of non-small cell lung cancer. Novartis has continued (and is continuing) to sell, import and offer dabrafenib for sale under the trademark Tafinlar® and those sales continue to erode sales of Zelboraf®.

NOVARTIS'S INFRINGEMENT OF THE '640 PATENT


20. The '640 patent was duly and legally issued on October 18, 2016, by the United Patent and Trademark Office ("PTO"). A true and correct copy of the '640 patent is attached as **Exhibit A** to this Complaint. By assignment, Plexxikon owns all right, title, and interest in and to the '640 patent. The application leading to the '640 patent was published on June 16, 2016.

21. The '640 patent has 12 claims, including independent claim 1. Independent claim 1 recites a compound of formula Ia:




or a pharmaceutically acceptable salt thereof, wherein: L₁ is a bond or —N(H)C(O)—; each R¹ is optionally substituted lower alkyl or optionally substituted heteroaryl; R² is hydrogen or halogen; R⁴ is hydrogen; R³ is optionally substituted lower alkyl or optionally substituted aryl; m is 0, 1, 2, 3, 4, or 5; and Ar is a monocyclic heteroaryl containing 5 to 6 atoms wherein at least one atom is nitrogen.

22. Dabrafenib (Tafinlar®) as sold, offered for sale, made, or imported by Novartis has the following formula, which infringes at least claim 1 of the '640 patent:




wherein: L_1 is a bond; each R^1 is optionally substituted lower alkyl or optionally substituted heteroaryl; R^2 is hydrogen; R^4 is hydrogen; R^3 is optionally substituted aryl; m is 2; and Ar is a monocyclic heteroaryl containing 5 to 6 atoms wherein at least one atom is nitrogen. The following is a direct comparison (in red) between the claimed Formula Ia and the formula of dabrafenib.

a. L_1 is a bond:




'640 patent




Dabrafenib

b. Each R^1 is optionally substituted lower alkyl or optionally substituted heteroaryl and $m=2$:




'640 patent




Dabrafenib

c. Ar is a monocyclic heteroaryl containing 5 to 6 atoms wherein at least one atom is nitrogen:




'640 patent




Dabrafenib

d. R² is hydrogen:




'640 patent




Dabrafenib

e. R³ is optionally substituted aryl:




'640 patent




Dabrafenib

f. R^4 is hydrogen:



'640 patent



Dabrafenib

23. Claim 11 recites a “method for treating a subject suffering from melanoma, thyroid cancer or colorectal cancer, said method comprising administering to the subject an effective amount of a compound of claim 1.”

24. Novartis also indirectly infringes at least Claim 1 and Claim 11 when third parties, for example McKesson as noted above, or other distributors, resellers, and healthcare providers, sell or offer to sell Tafenlar® in the United States, or import Tafenlar® into the United States, and for example, when healthcare providers, patients, and others use or administer Tafenlar® in the United States.

25. For example, Novartis represents in its Prescribing Information that “TAFINLAR® is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.” Exhibit B at §1.1 (also available at <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tafinlar.pdf>); *see also* Exhibit C (“Tafenlar and Mekinist Dosing Guide”). Novartis recommends that healthcare providers and patients administer the drug in specific amounts at specific time intervals:

The recommended dosage regimen of TAFINLAR is 150 mg orally taken twice daily, approximately 12 hours apart as a single agent or with trametinib. Continue treatment until disease progression or unacceptable toxicity occurs.

Take TAFINLAR at least 1 hour before or 2 hours after a meal [see Clinical Pharmacology (12.3)]. Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR. Do not open, crush, or break TAFINLAR capsules.

1 *See, e.g., id.* §2.2. Similarly, Novartis directs healthcare providers to “Instruct patients to take TAFINLAR
 2 at least 1 hour before or at least 2 hours after a meal [see Dosage and Administration (2.2)].” *See, e.g., id.*
 3 §17. Likewise, Novartis gives clear dosing instructions to patients:

- 4 • Take TAFINLAR exactly as your healthcare provider tells you. Do not
 5 change your dose or stop TAFINLAR unless your healthcare provider
 6 tells you.
- 7 • Take TAFINLAR 2 times a day, about 12 hours apart.
- 8 • Take TAFINLAR at least 1 hour before or 2 hours after a meal.
- 9 • Do not open, crush, or break TAFINLAR capsules.
- 10 • If you miss a dose of TAFINLAR, take it as soon as you remember. If
 11 it is within 6 hours of your next scheduled dose, just take your next dose
 12 at your regular time. Do not make up for the missed dose.

13 *See, e.g., id.* at Medication Guide (p. 30 of Exhibit B).

14 26. Novartis also encourages and promotes TAFINLAR[®] for sale by third parties and
 15 administration by healthcare providers and patients by touting its success in treating melanoma and/or
 16 BRAF V600E mutations. *See, e.g., id.* §14.1 (“The BREAK-3 study demonstrated a statistically
 17 significant increase in progression-free survival in the patients treated with TAFINLAR [as a single
 18 agent]”); Exhibit D (Novartis Oncology advertisement: “When Tafinlar is used with Mekinist, the
 19 combination has been shown to slow tumor growth more than either drug alone”); Exhibit E (Novartis
 20 October 23, 2017 Press Release announcing its “Breakthrough Therapy Designation,” which is reserved
 21 for “those that treat a serious or life threatening disease or condition and demonstrate a substantial
 22 improvement over existing therapies,” for the “adjuvant treatment of patients with stage III melanoma
 23 with a BRAF V600 mutation following complete resection”); Exhibit F (September 11, 2017 Novartis
 24 Press Release showing 53% reduction of risk of disease recurrence in patients with resected BRAF V600
 25 mutation-positive melanoma).

26 **EVIDENCE OF GSK’S COPYING**

27 27. GSK (or SmithKline Beecham Corporation, which merged with Glaxo Wellcome to form
 28 GSK in 2000) began filing patent applications on non-selective wild-type BRAF kinase inhibitors as early
 as November 20, 2000. Over the next seven years, GSK filed at least ten patent applications directed to

1 wild-type BRAF kinase inhibitors. None of these applications disclosed a core molecular structure
2 comprising a sulfonamide with its nitrogen attached to a halogenated phenyl.

3 28. In September of 2005, Plexxikon's CEO, Peter Hirth, approached GSK, disclosed the
4 genetic target of Plexxikon's selective kinase inhibitors, and offered to engage in a dialogue about possible
5 collaboration. Plexxikon needed a partner to conduct large clinical trials and introduce a drug to the
6 market. GSK was enthusiastic about the possible collaboration and, as a result, Plexxikon and GSK entered
7 into a Confidential Disclosure Agreement ("CDA") on October 14, 2005.

8 29. Pursuant to that CDA, Plexxikon met with scientists from GSK's biology team on
9 November 18, 2005. GSK was represented at the meeting by, among others, Pearl Huang (GSK's Vice
10 President of Oncology Biology) and Jerry Adams (GSK's Director of Medicinal Chemistry and, later, a
11 developer of Novartis's infringing dabrafenib product).

12 30. On January 17, 2006, Plexxikon hosted the biology team from GSK at its laboratory in
13 Berkeley, California. At that meeting, Plexxikon gave GSK detailed information about how the mutated
14 BRAF kinase was involved in oncology and the efficacy of Plexxikon's inventions in cellular and animal
15 models. After that meeting, Pearl Huang (one of the two GSK vice presidents who attended) sent a follow
16 up email noting that Plexxikon's "outstanding science makes the prospect of working together very
17 attractive" and that she was "very excited about the possibility of developing multiple compounds for
18 BRAFV600E [sic]."

19 31. Following that meeting, on January 27, 2006, GSK wrote to ask "whether Plexxikon would
20 be amenable to executing a Material Transfer Agreement with GSK so that we could evaluate some of the
21 Plexxikon compounds in-house?" Plexxikon agreed, and the parties then negotiated and ultimately signed
22 a Material Transfer Agreement ("MTA") dated June 1, 2006. Among other things, the MTA prohibited
23 GSK from making derivatives of or attempting to determine the molecular structure of the transferred
24 compounds and provided that Plexxikon would own any derivatives which GSK did make.

25 32. After GSK signed the MTA, and relying on its protections, Plexxikon shipped 10 mg of
26 each of vemurafenib, then known as PLX4032, and another Plexxikon-discovered selective BRAF kinase
27 inhibitor, known as PLX6098, to GSK's laboratory in Collegeville, PA. From that point up until August
28 2, 2006, GSK conducted due diligence (including *in vitro* studies) to confirm the activity of Plexxikon's

1 molecules. That diligence culminated in a GSK report, dated August 2, 2006, confirming the activity of
2 Plexxikon's molecules.


3 33. On the same day that GSK issued its diligence report, Plexxikon and GSK entered into a
4 Confidential Disclosure Agreement with the law firm of Woodcock Washburn. Pursuant to this agreement,
5 Plexxikon disclosed the structure of PLX4032 to Woodcock Washburn so that it could perform a prior art
6 search. Woodcock Washburn was prohibited from disclosing the structure of PLX4032 to GSK.
7 Woodcock Washburn delivered its (favorable) report on the prior art to both Plexxikon and GSK on
8 September 20, 2006.

9 34. Plexxikon and GSK continued to discuss GSK's desire to license Plexxikon's technology.
10 Between March 2006 and September 2006, the parties exchanged numerous term sheets. However, the
11 parties could not reach a business arrangement, and Plexxikon ultimately entered into a development and
12 licensing agreement with a different party.


13 35. The first publication of Plexxikon's core molecular structure occurred on January 4, 2007,
14 in Plexxikon's international patent application publication WO2007/002433. This was followed with an
15 article in Proceedings of the National Academy of Sciences (PNAS) on February 26, 2008, disclosing
16 Plexxikon's core molecular structure and discussing the importance of this structure in selectively binding
17 with the BRAF kinase produced due to the V600E mutation. The article explained that "[t]he critical
18 binding determinant for oncogenic selectivity derives from the interaction between the sulfonamide and
19 the beginning of the DFG region that subsequently directs the attendant alkyl chain into a small pocket
20 unique to the Raf family." (James Tsai et al., *Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase*
21 *with Potent Antimelanoma Activity*, 105 PROCEEDINGS NAT'L ACAD. SCI. 3041, 42 (2008),
22 www.pnas.org/content/105/8/3041).

23 36. Mere months later, on May 6, 2008, GSK filed its first patent application—provisional
24 patent application serial number 61/050,744—disclosing a sulfonamide with its nitrogen attached to an
25 optionally halogenated phenyl. This same patent application was also the first in which GSK disclosed a
26 selective kinase inhibitor targeting BRAF V600E. GSK filed this patent application more than a year after
27 Plexxikon filed its first relevant patent application, and nearly one year after the priority date of the '640
28 patent, July 17, 2007. The compound formula I disclosed in GSK's application is shown below


(reproduced from US 7,994,185 B2, column 3, lines 30-40), next to formula Ia of the '640 patent. GSK's infringing dabrafenib compound is also shown for comparison.



GSK's formula I




'640 patent formula Ia




Dabrafenib


37. As these diagrams show, each of the GSK formula I, dabrafenib, and the '640 patent formula Ia have the same core molecular structure:



GSK's formula I




Dabrafenib




'640 patent formula Ia


a. a structure that includes a sulfonamide, which binds to the kinase that results from BRAF^{V600E} mutation; and



GSK's formula I




Dabrafenib




'640 patent formula Ia


- b. a halogenated phenyl (which stabilizes the binding of the sulfonamide to the mutated kinase) attached to the nitrogen of the sulfonamide.



GSK's formula I



Dabrafenib



'640 patent formula Ia

38. GSK was aware that this core structure was responsible for selective binding to the kinase produced by BRAF^{V600E}. For example, GSK published an article on June 16, 2011, stating that “[e]valuation of several different headgroup linkers . . . revealed that the sulfonamide-containing analog 11 showed a substantial improvement in cellular potency, particularly in the pERK mechanistic assay run in B-Raf^{V600E} mutant SKMEL28 cells. . . . Thus, the sulfonamide N-H appeared to be a key pharmacophore for potent in vitro activity in this series.” (John C. Stellwagen et al., *Development of Potent B-RafV600E Inhibitors Containing an Arylsulfonamide Headgroup*, 21 BIOORGANIC & MED. CHEMISTRY LETTERS 4436, 37-38 (2011)). In this same article, GSK referenced Plexxikon’s earlier novel compounds, stating that “[t]his is similar to the binding modes observed for the sulfonamide groups in the B-Raf inhibitors PLX4720 and PLX4032.” *Id.* at 4438.

39. Further, GSK published another article on February 7, 2013, describing its development of dabrafenib and touting the importance of the core molecular structure that Plexxikon had developed: “Having established the sulfonamide as a key pharmacophore required for potent cellular inhibition of B-Raf^{V600E},” the authors explained, “we performed significant structural modifications elsewhere to lower the molecular weight and reduce the number of metabolic sites contained within the template.” (Tara R. Rheault et al., *Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors*, 4 ACS MED. CHEMISTRY LETTERS 358 (2011)).

40. The facts establish that GSK: had access to Plexxikon’s revolutionary selective BRAF kinase inhibitors having a core molecular structure of a sulfonamide with its nitrogen attached to a halogenated phenyl; confirmed the activity of Plexxikon’s selective BRAF kinase inhibitors; confirmed the novelty of Plexxikon’s selective BRAF kinase inhibitors; wanted to license them; and failed to come

1 to commercial terms with Plexxikon. Thereafter, GSK developed a selective BRAF kinase inhibitor that
 2 incorporated Plexxikon's novel core molecular structure that is selective to BRAF V600E. This occurred
 3 well over one year after Plexxikon made its novel selective BRAF kinase inhibitors public in a published
 4 patent application. In short, there is substantial evidence to suggest that GSK built dabrafenib by copying
 5 Plexxikon's invention.

6 **COUNT I**

7 **(DIRECT INFRINGEMENT OF U.S. PAT. NO. 9,469,640)**

8 41. Plexxikon incorporates each of the preceding paragraphs as if fully set forth herein.

9 42. The commercial use, manufacturing, offer for sale, sale and/or importation of dabrafenib,
 10 sold under the trademark Tafenlar®, by Novartis does and will constitute an act of infringement of one or
 11 more claims of the '640 patent.

12 43. Novartis has committed and continues to commit these acts of infringement without license
 13 or authorization.

14 44. Unless Novartis is enjoined from infringing the '640 patent, Plexxikon will suffer
 15 irreparable injury for which damages are an inadequate remedy.

16 45. As a result of Novartis's infringement of the '640 patent, Plexxikon has suffered damages
 17 pursuant to 35 U.S.C. § 284.

18 46. At least as of the filing of this Complaint, if not earlier, Novartis knows or should know
 19 that its selling, offering to sell, and/or importing Tafenlar®, does and will constitute an unjustifiably high
 20 risk of infringement of the '640 patent.

21 47. Novartis had actual notice of the published patent application that led to the '640 patent.
 22 The invention claimed in the '640 patent is substantially identical to the invention claimed in that
 23 published patent application.

24 48. Novartis is selling, offering to sell, and/or importing Tafenlar® despite its knowledge that
 25 its actions do and will constitute infringement of a valid patent. Novartis has intended to, and continues to
 26 intend to, directly infringe a valid patent. Thus, Novartis's infringement is willful.

27 49. Novartis, as successor-in-interest to GSK, knew or should have known of any copying on
 28 GSK's part of Plexxikon's novel structure to develop Tafenlar®.

50. The history of improper development of Tafenlar[®] combined with Novartis's ongoing deliberate, willful, and wanton infringement of the '640 patent, makes this case exceptional pursuant to 35 U.S.C. § 285.

COUNT II

(INDUCEMENT OF INFRINGEMENT OF U.S. PAT. NO. 9,469,640)

51. Plexxikon incorporates each of the preceding paragraphs as if fully set forth herein.

52. At least as of the filing of the original Complaint on August 3, 2017 (ECF No. 1), if not earlier, Novartis knew or should have known that the use, sale, offer for sale, and/or importation of Tafenlar[®], by itself and others, infringes the '640 patent.

53. Novartis has been and is actively and knowingly inducing, encouraging, assisting, and abetting others to infringe the '640 patent in the United States, including (a) distributors, resellers, healthcare providers, and other companies and sales agents, such as McKesson noted above, when those third parties use, sell, offer to sell, import, and otherwise promote and distribute Tafenlar[®]; and (b) healthcare providers, patients and others who use or administer Tafenlar[®] for the treatment of melanoma.

54. Novartis knew that the use, sale, offer for sale, and/or importation of Tafenlar[®] by others, including the administration or use of Tafenlar[®] for the treatment of melanoma, would be an act of direct infringement of the '640 patent, and that at least its Prescribing Information and other advertisements would actively induce direct infringement of the '640 patent. Despite such knowledge, Novartis continues to actively induce the infringement of the '640 patent by others. For example, Novartis continues to publish Prescribing Information and other advertisements on its website. *See, e.g.*, Exhibits B-D.¹ Novartis has also continued issuing Press Releases regarding the use of Tafenlar[®] for the treatment of melanoma after the original Complaint was filed in this case. *See, e.g.*, Exhibits E and F, dated October 23, 2017 and September 11, 2017, respectively.

55. Novartis actually knew or should have known that its actions would induce direct infringement of a valid patent. Novartis has intended to, and continues to intend to, induce others to directly infringe a valid patent. Novartis's indirect infringement is therefore willful.

¹ Each of Exhibits B-D were retrieved from www.novartis.com on October 25, 2017.

56. As a result of Novartis's inducement of infringement of the '640 patent, Plexxikon has suffered damages, including lost profits.

COUNT III

(CONTRIBUTORY INFRINGEMENT OF U.S. PAT. NO. 9,469,640)

57. Plexxikon incorporates each of the preceding paragraphs as if fully set forth herein.

58. At least as of the filing of the original Complaint on August 3, 2017 (ECF No. 1), and likely earlier, Novartis knew or should have known that the use, sale, offering for sale, and/or importation of Tafenlar®, by itself and others, infringes the '640 patent.

59. Novartis has been and is contributing to the infringement of the '640 patent in the United States by offering to sell, selling, importing or otherwise distributing Tafenlar®.

60. Plexxikon alleges under Federal Rule of Civil Procedure 11(b)(3) that, after a reasonable opportunity for further investigation and discovery, Plexxikon will likely have evidentiary support to show that (i) Novartis knew of the '640 patent at a time when Tafenlar® had no substantial non-infringing use other than the treatment of melanoma and (ii) that its sales to health care providers at that time contributed to the direct infringement of claims 11 and 12 by such health care providers when they administered Tafenlar® to patients for the treatment of melanoma.

61. As a result of Novartis's contributory infringement of the '640 patent, Plexxikon has suffered damages, including lost profits.

REQUEST FOR RELIEF

Wherefore, Plexxikon requests the following relief:

(a) Judgment that Novartis infringes one or more claims of the '640 patent due to its past and present commercial offer for sale, sale and/or importation of dabrafenib, trade name Tafenlar®;

(b) An injunction enjoining Novartis, and all persons acting in concert with Novartis, from selling, offering for sale, or importing Tafenlar®, or any other product the making, using, selling, offering for sale, or importing of which infringes one or more claims of the '640 patent;

(c) Judgment awarding Plexxikon damages adequate to compensate Plexxikon for Novartis's infringement of the '640 patent, with pre-judgment and post-judgment interest and costs pursuant to 35 U.S.C. § 284;

(d) Judgment that Novartis's infringement has been willful and that the damages awarded Plexxikon be trebled pursuant to 35 U.S.C. § 284;

(e) Judgment awarding Plexxikon reasonable royalties under 35 U.S.C. §154(d);

(f) A declaration that this is an exceptional case and an award of attorneys' fees pursuant to 35 U.S.C. § 285;

(g) An award of Plexxikon's costs and expenses in this action; and

(h) Such further and other relief as this Court may deem just and proper.

JURY DEMAND

Plaintiff demands trial by jury on all issues so triable.

DATED: November 2, 2017

Respectfully submitted,
YOUNG BASILE HANLON & MACFARLANE, P.C.

By: /s/ Jeffrey D. Wilson
Jeffrey D. Wilson (Pro Hac Vice)
wilson@youngbasile.com
Andrew R. Basile, Jr. (SBN 208396)
abasile@youngbasile.com

-and-

DURIE TANGRI LLP
Daralyn J. Durie (SBN 169825)
ddurie@durietangri.com
Clement S. Roberts (SBN 209203)
croberts@durietangri.com
Raghav Krishnapriyan (SBN 273411)
rkrishnapriyan@durietangri.com

Attorneys for Plaintiff Plexxikon Inc.

CERTIFICATE OF SERVICE

The undersigned attorney hereby certifies that on November 2, 2017, the foregoing was caused to be filed with the Court by electronic filing protocols, and that same will therefore be electronically served upon all attorneys of record registered with the Court's ECF/CM system.

By: /s/ Jeffrey D. Wilson
Jeffrey D. Wilson (*Pro Hac Vice*)